Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
7 pending office actions • 3 clients • 6 examiners • 2 art units • 0 of 7 (0%) have an AI response strategy ready
COZEN O'CONNOR (Alnylam) operates in the Biotechnology & Pharmaceuticals technology area, with 4 pending office actions currently active. This work is part of the firm's broader career history of 19375 applications. The 4 pending office actions represent the current focus for this specific set of files. The firm's experience in Biotechnology & Pharmaceuticals is supported by their 19375 career applications.
The firm maintains a resolved allowance rate of 85.65 percent, a figure calculated from their 19375 career applications. This 85.65 percent rate serves as a benchmark for the outcomes of their patent filings. Prosecution involves an average of 3.35 office actions per allowance, a metric that describes the typical interaction with patent examiners. For practitioners, this 3.35 average is a key indicator of the effort required to reach an allowance. The 4 pending office actions are managed alongside this 85.65 percent allowance rate and 3.35 office action average. These statistics provide a clear view of the firm's historical and current performance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (43%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, CHRISTINA L | 2 | 51.6% | +48.2% |
| CHONG, JASON Y | 1 | 73.3% | +18.1% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| ZAHORIK, AMANDA MARY | 1 | 57.8% | +49.0% |
| MONTGOMERY, STEPHEN EDWARD | 1 | — | — |
| NGUYEN, KHANH TUAN | 1 | 74.6% | +18.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 49d |
| 18897206 | PROCESS AND APPARATUS FOR CHEMICALLY TREATING A CARBON-CONTAINING FEEDSTOCK | CHONG, JASON Y | — |
| 18394838 | PROCESSES FOR PRODUCING AND REPROCESSING A RECYCLABLE ETHYLENE-VINYL ESTER POLYMER | MONTGOMERY, STEPHEN EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 49d |
| 18897206 | PROCESS AND APPARATUS FOR CHEMICALLY TREATING A CARBON-CONTAINING FEEDSTOCK | CHONG, JASON Y | — |
| 18613537 | 3'-OH RNA-CONTAINING OLIGONUCLEOTIDE DEPROTECTION | CHO, DAVID H | — |
| 18577377 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | ZAHORIK, AMANDA MARY | — |
| 18142234 | INORGANIC SOLID PARTICLE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | NGUYEN, KHANH TUAN | — |
| 18015202 | Circular siRNAs | TRAN, CHRISTINA L | — |
| Client (Assignee) | Pending OAs |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | 4 |
| Braskem | 2 |
| Case Western Reserve University | 1 |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1761 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18897206 | PROCESS AND APPARATUS FOR CHEMICALLY TREATING A CARBON-CONTAINING FEEDSTOCK | Braskem America, Inc. | CHONG, JASON Y | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 | |
| 18613537 | 3'-OH RNA-CONTAINING OLIGONUCLEOTIDE DEPROTECTION | Alnylam Pharmaceuticals, Inc. | CHO, DAVID H | §102§103§112DP | Non-Final OA | — | Pending | Mar 22, 2024 | |
| 18577377 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | Alnylam Pharmaceuticals, Inc. | ZAHORIK, AMANDA MARY | §103 | Non-Final OA | — | Pending | Jan 08, 2024 | |
| 18394838 | PROCESSES FOR PRODUCING AND REPROCESSING A RECYCLABLE ETHYLENE-VINYL ESTER POLYMER | Case Western Reserve University | MONTGOMERY, STEPHEN EDWARD | §103§112 | Non-Final OA | — | Pending | Dec 22, 2023 | |
| 18142234 | INORGANIC SOLID PARTICLE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | Braskem America, Inc. | NGUYEN, KHANH TUAN | 1761 | §103 | Final Rejection | — | Pending | May 02, 2023 |
| 18015202 | Circular siRNAs | Alnylam Pharmaceuticals, Inc. | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | — | Pending | Jan 09, 2023 |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. | TRAN, CHRISTINA L | 1637 | §103§112Other | Final Rejection | 49d | Pending | Nov 16, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial